Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
•
MET+
Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?
Answer from: Medical Oncologist at Academic Institution
Not at present and nothing is FDA approved or NCCN guidelines. Second line or later yes, especially on a trial
Comments
Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
Agree that currently no FDA approved agents upfron...
1337
Sign in or Register to read more
5124
Related Questions
How would you approach first-line treatment in metastatic NSCLC for a patient with ALK-EML4 V3a/b variant and MSI-high status?
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Agree that currently no FDA approved agents upfron...